Inflammatory Bowel Disease: Understanding Therapeutic Effects of Distinct Molecular Inhibitors as the Key to Current and Future Advanced Therapeutic Strategies
Open Access
- 30 October 2025
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2667
Abstract
The pathogenesis of Inflammatory Bowel Disease is complex and not completely understood, resulting from multifactorial interactions between genetic predisposition, environmental triggers, and dysregulation of both innate and adaptive immune responses. Cytokines, produced by dysregulated immune cells, trigger chronic intestinal inflammation leading to tissue damage, carcinogenesis, and disease perpetuation. Current advanced therapies—including tumor necrosis factor (TNF)-α antagonists, adhesion and trafficking inhibitors (such as anti-integrin agents and sphingosine-1-phosphate receptor modulators), interleukin inhibitors, and Janus kinase inhibitors—have improved patient outcomes, but targeting a single inflammatory pathway is often insufficient for long-term disease control. To further improve therapeutic efficacy, novel approaches are under investigation, including advanced combination therapies that simultaneously inhibit multiple pro-inflammatory pathways and microbiome-based treatments to restore intestinal homeostasis. In this evolving therapeutic scenario, precision medicine and advanced combination therapies appear promising for breaking through the current therapeutic ceiling. This review highlights current knowledge on the role of cytokines in IBD pathogenesis and explores how their modulation can modify and control disease course.Keywords
This publication has 117 references indexed in Scilit:
- Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease ManagementDrugs, 2024
- Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligenceUnited European Gastroenterology Journal, 2024
- Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary CenterDigestive Diseases and Sciences, 2023
- Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapiesBiomedicine & Pharmacotherapy, 2022
- Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial programContemporary Clinical Trials, 2022
- Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational studyUnited European Gastroenterology Journal, 2021
- Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel diseaseInflammation Research, 2021
- Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibitionPharmacology Research & Perspectives, 2019
- Anti‐JC virus antibodies: Implications for PML Risk StratificationAnnals of Neurology, 2010
- Safety and tolerability of concurrent natalizumab treatment for patients with Crohnʼs disease not in remission while receiving infliximabInflammatory Bowel Diseases, 2007